

Title (en)
TRPC4 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF PAIN

Title (de)
TRPC4 MODULATOREN ZUR VERWENDUNG BEI DER BEHANDLUNG ODER PRÄVENTION VON SCHMERZEN

Title (fr)
MODULATEURS TRPC4 À UTILISER DANS LE TRAITEMENT OU LA PRÉVENTION DE LA DOULEUR

Publication
EP 3485889 A1 20190522 (EN)

Application
EP 18191329 A 20121214

Priority
• US 201161576619 P 20111216
• EP 12806318 A 20121214
• US 2012069753 W 20121214

Abstract (en)
The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.

IPC 8 full level
A61K 31/4709 (2006.01); **A61K 31/00** (2006.01); **A61P 29/02** (2006.01)

CPC (source: EP US)
A61K 31/00 (2013.01 - EP US); **A61K 31/4709** (2013.01 - EP US); **A61K 45/06** (2013.01 - US); **A61P 29/02** (2017.12 - EP US); **C07D 215/38** (2013.01 - EP US)

Citation (applicant)
• LANCET, vol. 353, no. 9170, 19 June 1999 (1999-06-19), pages 2145 - 2148
• MILLER ET AL., J. BIOL. CHEMISTRY, vol. 286, pages 33436 - 33446
• FREIREICH, CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1966, pages 219 - 244
• "Pharmaceutical dosage forms and drug delivery systems", 1999, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
• "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
• GOODMAN; GILMAN'S ET AL.: "The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL PROFESSIONAL
• ROWE, R. C. ET AL.: "Handbook of Pharmaceutical Excipients", 2003, APHA PUBLICATIONS
• D'AMOUR ET AL., J. PHARMACOL. EXP. AND THER., vol. 72, 1941, pages 74 - 79
• RANDALL ET AL., ARCH. INT. PHARMACODYN, vol. 111, 1957, pages 409 - 419
• VINEGAR ET AL., J. PHARMACOL. EXP. THER., vol. 166, 1969, pages 96 - 103
• DUBUISSON ET AL., PAIN, vol. 4, 1977, pages 161 - 174
• KIM ET AL., PAIN, vol. 50, 1992, pages 355 - 363
• CHAPLAN ET AL., J. NEUROSCI. METHODS, vol. 53, 1994, pages 55 - 63
• BENNETT ET AL., PAIN, vol. 33, 1988, pages 87 - 107
• HARGREAVES ET AL., PAIN, vol. 32, 1998, pages 77 - 88
• GOGAS ET AL., ANALGESIA, vol. 3, 1997, pages 111 - 118
• ROGER E. KIRK: "Experimental Design: Procedures for the Behavioral Sciences", 1994, WADSWORTH PUBLISHING

Citation (search report)
• [XY] WO 0064877 A1 20001102 - NEUROGEN CORP [US], et al
• [X] WO 03053915 A2 20030703 - SCHERING CORP [US]
• [X] WO 03024899 A2 20030327 - BRISTOL MYERS SQUIBB CO [US], et al
• [X] US 5656449 A 19970812 - YUE STEPHEN T [US]
• [Y] WO 03057843 A2 20030717 - ALGOS THERAPEUTICS INC [US], et al
• [Y] WO 2011022638 A1 20110224 - TRANSPOSAGEN BIOPHARMACEUTICALS INC [US], et al
• [X] US 2004082779 A1 20040429 - VOS TRICIA J [US], et al
• [X] JACOBS WINSTEIN ET AL: "a-Piperidyl-4-quinolinemethanols Substituted in the 2-Position", 1 January 1946 (1946-01-01), XP055570382, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/ja01216a090> [retrieved on 20190318]
• [X] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OCHIAI, ELJI ET AL: "Synthesis of 2'-substituted Cinchona alkaloids", XP002789808, retrieved from STN Database accession no. 1961:106009
• [X] ANDREA CAPPELLI ET AL: "Further Studies on the Interaction of the 5-Hydroxytryptamine 3 (5-HT 3) Receptor with Arylpiperazine Ligands. Development of a New 5-HT 3 Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 10, 1 May 2005 (2005-05-01), US, pages 3564 - 3575, XP055570456, ISSN: 0022-2623, DOI: 10.1021/jm0493461
• [Y] M. MILLER ET AL: "Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 38, 23 September 2011 (2011-09-23), pages 33436 - 33446, XP055053586, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.274167
• [X] ZARAGOZA F ET AL: "2-(4-Alkylpiperazin-1-yl)quinolines as a New Class of Imidazole-Free Histamine H3 Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 48, no. 1, 1 January 2005 (2005-01-01), pages 306 - 311, XP002346282, ISSN: 0022-2623, DOI: 10.1021/JM040873U

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2013090722 A1 20130620; AU 2012352083 A1 20140717; AU 2012352083 B2 20180104; AU 2018202172 A1 20180426; AU 2018202172 B2 20191219; CA 2859283 A1 20130620; CA 2859283 C 20210309; CY 1121293 T1 20200529; DK 2790687 T3 20181119; EP 2790687 A1 20141022; EP 2790687 B1 20180829; EP 3485889 A1 20190522; EP 3485889 B1 20230906; ES 2692546 T3 20181204; HR P20181746 T1 20181228; HU E041294 T2 20190528; JP 2015500345 A 20150105; JP 2018030875 A 20180301; JP 2019135271 A 20190815; JP 6534716 B2 20190626; JP 6858808 B2 20210414; LT 2790687 T 20181210; PL 2790687 T3 20190329;

PT 2790687 T 20181113; RS 57919 B1 20190131; SI 2790687 T1 20190131; TR 201815535 T4 20181121; US 10131634 B2 20181120;
US 2014329856 A1 20141106; US 2019135759 A1 20190509

DOCDB simple family (application)

US 2012069753 W 20121214; AU 2012352083 A 20121214; AU 2018202172 A 20180327; CA 2859283 A 20121214; CY 181101105 T 20181025;
DK 12806318 T 20121214; EP 12806318 A 20121214; EP 18191329 A 20121214; ES 12806318 T 20121214; HR P20181746 T 20181024;
HU E12806318 A 20121214; JP 2014547485 A 20121214; JP 2017195744 A 20171006; JP 2019099299 A 20190528; LT 12806318 T 20121214;
PL 12806318 T 20121214; PT 12806318 T 20121214; RS P20181246 A 20121214; SI 201231425 T 20121214; TR 201815535 T 20121214;
US 201414303711 A 20140613; US 201816154478 A 20181008